Organogenesis Inc

128 articles about Organogenesis Inc

• Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors

  5/5/2022

  Organogenesis Holdings Inc. announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to the Company’s Board of Directors, effective May 3, 2022.

• Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

  4/5/2022

  Organogenesis Holdings Inc. today announced that first quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, May 10th.

• Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference

  3/8/2022

  Organogenesis Holdings Inc. announced that company management will participate in Oppenheimer’s 32nd Annual Healthcare Conference, which is being held virtually from March 15th-16th.

• Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors

  2/17/2022

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced the appointment of Michael J. Driscoll, Ed.D. to the Company’s Board of Directors, effective February 15, 2022.

• Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February 2022

  2/11/2022

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced that company management will participate in the following upcoming investor conferences:

• Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

  2/7/2022

  Organogenesis Holdings Inc. today announced that fourth quarter and fiscal year 2021 financial results will be reported after the market closes on Tuesday, March 1st.

• Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

  11/22/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021.

• Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results

  11/9/2021

  Organogenesis Holdings Inc. reported financial results for the three and nine months ended September 30, 2021.

• Organogenesis Holdings Inc. to Participate in the Credit Suisse 30th Annual Healthcare Conference

  11/8/2021

  Organogenesis Holdings Inc. today announced that company management will participate in the Credit Suisse 30th Annual Healthcare Conference, which is being held virtually from November 8th-11th.

• Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

  10/7/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced that third quarter of fiscal year 2021 financial results will be reported after the market closes on Tuesday, November 9th.

• Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results

  8/9/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the three and six months ended June 30, 2021.

• Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank

  8/9/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced a new credit agreement with Silicon Valley Bank, the lead agent, and several other lenders.

• Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021

  7/2/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced that second quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, August 9th.

• Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

  5/10/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the three months ended March 31, 2021.

• Organogenesis Appoints Jon Giacomin to Board of Directors

  5/10/2021

  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company’s Board of Directors, effective May 7, 2021.

• Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting

  5/6/2021

  Organogenesis Holdings Inc. announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and Nushield® product lines will be showcased at the 2021 Symposium on Advanced Wound Care Spring | Wound Healing Society Virtual Experience, held May 10-14.

• Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021

  4/12/2021

  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, May 10.

• Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance

  3/16/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the three and twelve months ended December 31, 2020 and introduced financial guidance expectations for fiscal year ended December 31, 2021.

• Organogenesis Appoints David C. Francisco as Chief Financial Officer

  2/16/2021

  Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of David C. Francisco as the Company’s Chief Financial Officer, effective February 15, 2021.

• Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

  2/9/2021

  - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences: The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference